• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

制药行业与医疗保健改革。

The pharmaceutical industry and health care reform.

作者信息

Lucas W L

机构信息

Pharmaceutical Manufacturers Association, Washington, DC 20005.

出版信息

J Health Care Poor Underserved. 1994;5(3):219-23; discussion 237-9. doi: 10.1353/hpu.2010.0081.

DOI:10.1353/hpu.2010.0081
PMID:7918890
Abstract

While the goals of President Clinton's health care reform plan--to expand access to health care by the underserved and reduce the unacceptably high cost of care--are important, his proposed mechanisms for doing so include provisions that are counterproductive. Blacklisting certain drugs from the Medicare program, imposing red tape on physicians who participate in Medicare, and establishing a Medicare rebate tax will hurt the pharmaceutical industry's ability to conduct research on new medications. In the end, the Administration's plan will injure the very population--the elderly, the poor, and minorities--that needs health care reform the most.

摘要

虽然克林顿总统医疗保健改革计划的目标——扩大医疗服务不足人群获得医疗保健的机会,并降低高得令人无法接受的医疗成本——很重要,但他为此提议的机制包括一些适得其反的条款。将某些药物列入医疗保险计划的黑名单、对参与医疗保险的医生设置繁文缛节,以及设立医疗保险回扣税,都会损害制药行业进行新药研究的能力。最终,政府的计划将伤害到最需要医疗保健改革的人群——老年人、穷人和少数族裔。

相似文献

1
The pharmaceutical industry and health care reform.制药行业与医疗保健改革。
J Health Care Poor Underserved. 1994;5(3):219-23; discussion 237-9. doi: 10.1353/hpu.2010.0081.
2
Meeting the needs of the poor and underserved under health care reform.在医疗保健改革中满足穷人和医疗服务欠缺人群的需求。
J Health Care Poor Underserved. 1994;5(3):240-6. doi: 10.1353/hpu.2010.0302.
3
How will drug and device makers fare under Clinton's reform plan?在克林顿的改革计划下,药品和器械制造商的情况会怎样?
Mater Manag Health Care. 1993 Nov;2(11):18, 20.
4
How physicians will benefit under Clinton's plan. A talk with Judith Feder, PhD. Interview by Amber Stenger.医生们将如何从克林顿的计划中受益。与朱迪思·费德博士的一次谈话。安伯·斯滕格采访。
Postgrad Med. 1994 Feb 15;95(3):49-50, 53-6.
5
Clinton's tooth-fairy financing.克林顿式的牙仙融资。
J Am Health Policy. 1993 Nov-Dec;3(6):14-9.
6
Clinton's breakthrough drug committee: will it stifle new drug development?克林顿的突破性药物委员会:它会扼杀新药研发吗?
Hosp Formul. 1993 Nov;28(11):946, 945.
7
Impact of the new US health-care-reform legislation on the pharmaceutical industry: who are the real winners?新美国医疗改革立法对制药行业的影响:谁是真正的赢家?
Clin Pharmacol Ther. 2010 Nov;88(5):589-92. doi: 10.1038/clpt.2010.167.
8
Pursuing cost containment in a pluralistic payer environment: from the aftermath of Clinton's failure at health care reform to the Balanced Budget Act of 1997.在多元支付方环境中追求成本控制:从克林顿医保改革失败的后果到1997年的《平衡预算法案》
Health Econ Policy Law. 2006 Jul;1(Pt 3):237-61. doi: 10.1017/S1744133106003033.
9
Physician payment disclosure under health care reform: will the sun shine?医改下的医师薪酬披露:阳光会普照吗?
J Am Board Fam Med. 2013 May-Jun;26(3):327-31. doi: 10.3122/jabfm.2013.03.120264.
10
The Rhetorical Transformations and Policy Failures of Prescription Drug Pricing Reform under the Trump Administration.特朗普政府下处方药定价改革的修辞转变与政策失败
J Health Polit Policy Law. 2021 Dec 1;46(6):1053-1068. doi: 10.1215/03616878-9349156.